logos csic

Skip Navigation LinksInglés (Estados Unidos) > Research > Papers > Paper detail

 

 

Lockpicking FGFR1 with aptamer-based technology.Lockpicking FGFR1 with aptamer-based technology.Nonatelli F, Pastor F, Calvo F.2025-02-26T23:00:00Z<p></p><div><h3>Abstract</h3><div><br></div><p>Targeting undruggable proteins and achieving high selectivity remain critical challenges in molecular therapeutics, as the lack of well-defined binding pockets, along with off-target effects leading to toxicity and reduced efficacy, often hampers drug development. The study by Zlinska et al.1 leverages aptamer technology to develop new molecular and therapeutic tools for fibroblast growth factor receptor-1 (FGFR1) modulation. It describes a novel DNA G-quadruplex aptamer (called VZ23), which specifically binds to FGFR1 without affecting other FGFR variants, effectively inhibiting FGFR1 signaling and its cellular responses (Figure 1). This finding offers new potential solutions for treating several pathologies where FGFR1 is relevant, including cancer, skeletal and developmental disorders, and metabolic syndromes.​​<br></p></div><p>​Mol Ther Nucleic Acids. 2025 Feb 27;36(1):102488.<br></p>487

 
IBBTEC

Instituto de Biomedicina y Biotecnología de Cantabria.
PCTCAN - Cl. Albert Einstein, 22
39011 Santander
ibbtec@unican.es

Sign In